Latest Tax Rebates News

Page 2 of 16
Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
Ada Torres
20 Oct 2026
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
TG Metals has advanced its Van Uden gold development and Lake Johnston lithium project, including a high-return heap-leach study and a maiden 6.71Mt lithium resource. But the ASX explorer ended September with A$1.523 million in cash, equivalent to just 1.05 quarters of funding at the reported spending rate.
Maxwell Dee
Maxwell Dee
19 Oct 2026
Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.
Victor Sage
Victor Sage
19 Oct 2026
Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.
Ada Torres
Ada Torres
16 Oct 2026
Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.
Ada Torres
Ada Torres
13 Oct 2026
Anson Resources has raised Green River’s modelled post-tax NPV8 to approximately US$1.046 billion after incorporating two conditional Utah incentives. The uplift leaves the project’s US$569 million capital estimate and lithium-price assumption unchanged, but the benefits remain tied to construction, performance and financing milestones.
Maxwell Dee
Maxwell Dee
7 Oct 2026
AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.
Victor Sage
Victor Sage
30 Sept 2026
AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.
Sophie Babbage
Sophie Babbage
29 Sept 2026
Latrobe Magnesium has secured A$8.5 million in equity funding to complete its Latrobe Valley demonstration plant and advance a proposed South Carolina magnesium project. The raising gives the company near-term funding certainty, but also brings further dilution and leaves the larger US development dependent on future capital.
Maxwell Dee
Maxwell Dee
22 Sept 2026
Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.
Ada Torres
Ada Torres
18 Sept 2026
Anson Resources has secured approval for an estimated US$212 million post-performance tax credit tied to its Green River Lithium Project in Utah. The benefit could materially improve the project’s projected economics, but it will only be realised if the project proceeds, generates tax revenue and meets the scheme’s conditions.
Maxwell Dee
Maxwell Dee
11 Sept 2026

Browse the archive

Full archive